Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells

KRAS is mutated in approximately 25% of Non-small Cell Lung Cancer (NSCLC) patients and first specific inhibitors showed promising responses that may be improved by concurrent interference with downstream signaling pathways. Cell lines exhibiting KRAS mutations show specific sensitivities to modulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Plangger, Adelina, Rath, Barbara, Hochmair, Maximilian, Funovics, Martin, Hamilton, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488304/
https://www.ncbi.nlm.nih.gov/pubmed/34598083
http://dx.doi.org/10.1016/j.tranon.2021.101230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488304/
https://www.ncbi.nlm.nih.gov/pubmed/34598083
http://dx.doi.org/10.1016/j.tranon.2021.101230

Ejemplares similares